Evidence map›Paper›PMID 42122558›Full record

ArticleSensors (Basel, Switzerland)2026

Development of a Highly Sensitive Analytical System for Measuring 17β-Estradiol Using Fluorescent Molecular Probes.

Yoshio Suzuki

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yoshio SuzukiHealth and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba 305-8566, Ibaraki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Easier measurement of 17β-estradiol could promote the early diagnosis and treatment of medical conditions in women. In this study, we developed a fluorescence-based assay using a nucleic acid aptamer labeled with a fluorescent dye for the detection of estrogen. Upon binding to 17β-estradiol, the aptamer undergoes a conformational change, resulting in a measurable change in fluorescence intensity. The assay enables rapid detection within 30 min, with a limit of detection of 0.2 pg/mL and a linear dynamic range of 1-1000 pg/mL. High selectivity toward 17β-estradiol was confirmed against structurally related compounds. The method was successfully applied to human saliva samples, demonstrating high sensitivity, precision, and reproducibility with recoveries of 98.8% and coefficients of variation below 3.0%. In addition, a compact desktop fluorescence detector was developed, allowing direct measurement in polymerase chain reaction tubes without sample transfer, thereby simplifying the procedure and minimizing sample loss. These results demonstrate that the proposed system provides a simple and practical platform for estrogen detection in biological samples and has potential applications in clinical and research settings.

Indexed as

Biosensing TechniquesEstradiolFluorescent DyesMolecular ProbesAptamers, NucleotideEstrogensFemaleHumansLimit of DetectionReproducibility of ResultsSalivaSpectrometry, FluorescenceAptamers, NucleotideEstradiolEstrogensFluorescent DyesMolecular Probesaptamerestrogenfluorescencemolecular probesportable device

Identifiers

PMID42122558
PMCPMC13166037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.